

Special Issue

New Trends in Vaccine Characterization, Formulations, and Development

Message from the Guest Editor

Over the last few decades, several platforms have been used for vaccine development, formulation, and delivery. Each platform has its own unique advantages over other platforms. This has led to the availability of different types of vaccines ranging from conventional attenuated or killed whole pathogen to subunit vaccines and, nucleic acid-based vaccines such as mRNA-based vaccines. Even though modern vaccines are proven to be safe and effective, they still suffer from numerous limitations such as poor thermostability, short shelf life at room temperature, and the requirement for specialized needles and syringes. To overcome these issues, new formulations and modes of vaccine delivery are currently under investigation. We would like to encourage submissions on recent advances made in vaccine characterization, formulation, and development, for which original research articles, reviews, communications, case reports, and clinical trials mentioning technological improvements in the field of vaccines are welcome. Papers describing novel formulations, the development of new platforms for vaccine delivery, identification of novel adjuvants, and novel modes of delivery are also welcome.

Guest Editor

Dr. Ravinder Kumar
Department of Biological Sciences, Rensselaer Polytechnic Institute,
Troy, NY 12180, USA

Deadline for manuscript submissions

closed (31 August 2025)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/128560

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).